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ABSTRACT
Deaf-blindness is a serious disability, which affects all aspects of life. The most common condition com-
bining deafness and blindness is the Usher syndrome (USH), which is traditionally divided into three ma-
jor clinical subtypes, including Usher syndrome type 1, Usher syndrome type 2, and Usher syndrome type 
3. The frequency of USH occurrence is often undervalued. To date, five genes for USH1 have been identified, 
three genes are involved in USH2, and one gene in USH3. In summary, USH can be a multisensory impair-
ment associated with hearing impairment, progressive retinal degeneration, and vestibular dysfunction. 
Management of these patients requires interdisciplinary approach and collaboration.
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INTRODUCTION
Hellen Keller is a great example and symbol of 
a person who can overcome deaf-blindness and still 
adapt to the society. However, every day we meet pa-
tients who have either deafness or blindness. When 
those two disabilities combine, the person is really 
isolated from the world. They can develop gradually 
or simultaneously, or most devastatingly—be present 
at birth. Usher syndrome (USH) comprises a series 
of inherited conditions characterized by the com-
bination of hearing impairment and visual impair-
ment by progressive retinal degeneration in the form 
of retinopathy pigmentosa. 
Usher syndrome not only comprises more than 
half of cases of deaf-blindness, but it is also the most 
common cause of combined vision and hearing loss 
(1). The frequency of occurrence, which is currently 
reported to be 4 to 17 per 100,000, may often be un-
dervalued (2).
Besides the usually congenital hearing loss, reti-
nitis pigmentosa is a gradual progressive process and 
is being first noticed in early childhood to the mid-
teenage years (2).
Nevertheless, USH encompasses more than just 
congenital deafness and retinitis pigmentosa. In ad-
dition, there may also be degeneration of the central 
nervous system with variable presentation of psychi-
atric illnesses, mental retardation, olfactory sensitiv-
ity loss, as well as aphasia, and other conditions (3,4).
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vere progression leading to blindness, USH1 is the 
most severe form of USH (15). Current data show 
that at least five genes (USH1B (MYO7A),  USH1C 
(harmonin),  USH1D,  USH1F (PCDH15), USH1G 
(SANS) and possibly  CIB2 (4,16) and seven loci 
have been described for USH1 families (12). Mu-
tation in the MYO7A gene is the most common in 
USH1 cases and was reported to be responsible 
for the subtype USH1B (17) in about 29% to 75% 
of cases (18–21). MYO7A  mutations are the most 
common cause of USH1, followed by mutations 
in CDH23 and PCDH15 (22).
Based on clinical features, patients with USH1 
present with vestibular dysfunction from birth and 
progressive vision loss due to retinitis pigmentosa 
(RP) (22) within the first decade of life with loss of 
vision by mid-life as well as severe to profound bilat-
eral congenital sensorineural hearing loss (6,23). 
However, wide phenotypic variations are pos-
sible and the cause for phenotype-genotype associa-
tions between the MYO7A mutations and the multi-
plicity of clinical symptoms are not entirely compre-
hended (24). 
The second of the three recognized clinical sub-
types, USH2 is characterized by congenital moder-
ate to severe hearing loss, a slightly later onset of RP 
during or after puberty and no vestibular dysfunction 
(25). Different than USH1, USH2 is slightly milder, but 
is the most common subtype and accounts for approx-
imately two-thirds of USH patients (26).
Even though USH1 and USH2 are in one group, 
clinical symptoms differ noticeably. In USH2 vestib-
ular symptoms are not present, hearing loss is less se-
vere and the onset of progressive retinal degeneration 
in the form of retinopathy pigmentosa occurs later 
(16).
In association with USH2 three genes have 
been identified including USH2A, GPR98 (USH2C), 
and DFNB31 (USH2D) (26). 
In most populations USH3 is the most rare-
ly represented form of the USH group with approxi-
mately 2–4% of all cases (6,27). An exception in this 
regard was described in Finnish (28) and Ashkenazi 
Jewish populations (26,29). The gene responsible for 
USH3 has been identified as the USH3A (clarin-1) 
gene (30).
The syndrome can be traditionally divided into 
three major clinical subtypes, Usher syndrome type 
1 (USH1), Usher syndrome type 2 (USH2), and Ush-
er syndrome type 3 (USH3). The subtypes are asso-
ciated with distinct genetic causes due to at least 12 
genetic chromosomal loci assigned to the three types 
(5–7). Each of the three clinical USH types is autoso-
mal recessive in inheritance (6,8,9). 
Usher syndrome is determined by mutations in 
specific genes, with five genes currently known for 
USH1, three genes for USH2, and one gene for USH3 
(4,10). 
A variety of proteins are encoded by these afore-
mentioned genes, which are expressed in both reti-
nal photoreceptors and inner ear hair cells that en-
code proteins from distinct protein classes and fam-
ilies, which likely interact in a protein network criti-
cal for the development and maintenance of the sen-
sorineural cells (11,12). Molecule absence or dysfunc-
tion in the interaction of protein complexes causes 
network disruption with sensorineural degeneration 
in the retina and inner ear, which leads to USH (5,13). 
Mutations lead to damage of certain nerve cells, such 
as the photoreceptors of the retina and the hair cells 
in the cochlea of the inner ear, causing a specific type 
of Usher syndrome depending on which gene locus is 
altered, which also affects the individual course. The 
affected genes are responsible for proteins that are in-
volved in vision, hearing as well as balance. The ex-
pression of subtypes varies based on the onset and 
severity of hearing loss and whether vestibular dys-
function is present or absence (7). 
Even though USH is traditionally divided into 
three subtypes, within the framework of onset and 
severity of common characteristics of hearing loss, 
presence or absence of vestibular symptoms, there 
may be a substantial overlap between the several 
clinical types with possible clinical variability in pre-
sentation and atypical presentations in all USH types 
(7).
Usher Syndrome Subtypes
Usher syndrome type 1 is characterized by pro-
found sensorineural congenital hearing loss com-
bined with pre-pubertal onset of retinitis pigmen-
tosa and severe  vestibular dysfunction (14). Caus-
ing congenital deafness, constant vestibular defi-
ciency, and prepubertal retinitis pigmentosa with se-
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Unlike the other types, patients with USH3 are 
asymptomatic at birth and show normal physiology 
and develop symptoms later in life with exhibition by 
mid-life of progressive deterioration of hearing and 
deafness with variable balance disorder and late vari-
able occurrence of RP (4,31,32) induced by mutations 
in the gene encoding clarin-1 (33,34).
Like the other types of USH, there is no avail-
able treatment for USH3 patients at present, neither 
to stop or to slow down the progression of the disease 
(33). There are options to symptomatically support 
patients for better management of symptoms, and 
also new therapeutic strategies that are based on new 
technologies including stem cell therapies, and gene 
replacement therapy are emerging (22). 
Where auditory impairment can be assisted by 
the help of bilateral hearing aid devices, there is cur-
rently no therapy available for RP, which is a diffi-
cult challenge for the patients and present research 
communities. 
Clinical Presentation of Vison Loss in Usher 
Syndrome Patients
Retinitis pigmentosa is a group of progressive 
bilateral degeneration of the rod and cone photore-
ceptors that are characterized first by night blindness 
that is followed by visual-field loss, resulting in se-
vere visual impairment (35).
The attention toward RP is focused on the de-
lay of the complete destruction of the photoreceptors 
as long as possible where in all three USH subtypes 
the ophthalmologic findings are presented by nar-
rowed retinal blood vessels, intraretinal pigmenta-
tion in a bone-spicule pattern, and waxy pallor of the 
optic disc (36). The most common cause of recessive 
retinitis pigmentosa (RP) including 18% of all RP is 
USH2 with visual acuity loss, and constricted visual 
field (1,37). As in other forms of RP, patients suffer-
ing from USH experience vision loss beginning with 
deterioration of peripheral and night vision (38).
However, RP develops with a different onset in 
each of the three USH subtypes with varying degrees 
of expression and varying vison prognosis (6). 
Patients affected by USH1 usually develop RP 
symptoms at prepubertal age (4), with vision declin-
ing generally more severely than patients affected 
by USH2 (39,40). Initially they present mainly with 
night blindness (nyctalopia), mid-periphery progres-
sive visual field loss by rod photoreceptor degenera-
tion (6), reaching tunnel vision within the first de-
cade of life. In the course the cone photoreceptors are 
involved with central blindness and patients reach 
the stage of legal blindness by midlife, in a period of 
15 years on average, due to RP (9,41). In retinal im-
aging patients present with signs of bone spicule pig-
mentation, atrophy or depigmentation of the retinal 
pigment epithelium, pallor of the optic disc, and at-
tenuation of the retinal arterioles (6) with possible 
cataract and macular edema formation in the course 
of the disease (9,21). 
USH2 patients usually have a later onset of RP, 
mostly within the first two decades of life (42) with 
useful but impaired vision into middle age (43). 
The rarest type, USH3, is characterized by post-
lingual progressive hearing loss and variable late on-
set of RP and vestibular dysfunction (44). 
MANAGEMENT
The clinical diagnosis of USH can be demand-
ing due to the various USH phenotypes, atypical 
forms of USH, and similarity to other syndromes 
(21). Unfortunately, little information is known of 
USH protein function, especially in the retina, with 
the consideration that the designated genes encode 
proteins believed to conduct various cellular func-
tions and that the USH proteins may function in 
multiprotein complexes in vivo (44). Thus, much ef-
fort with much research work on solving pathophys-
iology and genetics of USH has been done (22). It is 
to date incurable, which leads to the fact that it is im-
portant to diagnose patients with USH early. 
In order to provide information on the USH 
subtype and determine the severity of the disease, 
patients should receive clinical geneticist consulta-
tion and genetic testing. This may identify USH pa-
tients before retinal involvement and may give them 
the chance to profit from novel gene therapy (45). 
Ophthalmic evaluation should include fun-
dus photography, dynamic visual field examination, 
Ganzfeld-ERG with a full-field electroretinography 
(ERG) to confirm the dysfunction or loss of function-
ality of photoreceptors and optical coherence tomog-
raphy (OCT) to obtain cross-sectional images of the 
retina to reveal possible cystic changes of the macu-
lar region or reduced central foveal thickness asso-
ciated with attenuation of the RPE layer and loss of 
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the photoreceptor layer (36,46,47). Further audiom-
etry, otoscopy, and balance evaluation with electro-
nystagmography to measure involuntary eye move-
ment (48).
As mentioned above, there is no known treat-
ment for USH and no approved treatment for the 
vision loss associated with RP (37). The treatment 
mainly concerns interventions to slow down the 
progress of the disease (46), with possible vitamin A 
palmitate (49), appropriate visual and hearing aids.
A large amount of gene research focuses on 
USH with gene-based therapies, genome editing, 
and numerous therapeutic strategies (50,51) with the 
hope to even better help USH patients in near future 
and improve their quality of life. 
CONCLUSION
Usher syndrome is a group of genetically auto-
somal recessive disorders characterized by clinical-
ly variable hearing loss and gradual visual impair-
ment secondary to RP and possible vestibular dys-
function. Considering that the affected persons often 
lose two of their vital human senses or can only use 
them in an impaired way, Usher syndrome must be 
considered as a disease that severely limits the qual-
ity of life of the patient. This is probably also one of 
the reasons why research has been making remark-
able steps with USH gene identification and under-
standing syndrome pathogenesis. In view of the pos-
itive results of the current studies, we wish that fur-
ther developed therapy approaches and supportive 
methods will be available. 
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